Form 4: Director Winston Kung Receives Equity Grant at Corbus
Statement of Changes in Beneficial Ownership
Director Winston Kung was granted 3,800 restricted stock units and 12,300 stock options by Corbus Pharmaceuticals.
Summary
- Director Winston Kung received a grant of 3,800 restricted stock units (RSUs) on May 19, 2026.
- The director was also granted 12,300 stock options with an exercise price of $9.15 per share.
- Both the RSUs and the stock options are scheduled to vest 100% on the one-year anniversary of the grant date.
- Following these transactions, the director's total beneficial ownership of common stock is 14,166 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Standardized vesting schedule ensures retention and long-term commitment from the director.
Negatives
- The issuance of new equity awards results in minor dilution to existing shareholders.
Risks
- Potential for future dilution if additional equity compensation plans are implemented.
- Market volatility affecting the value of the granted options and RSUs.
Future Outlook
The equity grants are part of the issuer's 2024 Equity Compensation Plan, indicating a continued strategy of using equity to incentivize board members.
Management Comments
- The grants were made in accordance with the terms of the issuer's 2024 Equity Compensation Plan.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to align board incentives with long-term clinical and commercial milestones.
Comparison to Industry Standards
- The use of one-year cliff vesting for director equity is consistent with standard practices for small-cap biotechnology firms.
- The grant size is typical for non-executive director compensation packages in the pharmaceutical industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of RSUs and options under the 2024 Equity Compensation Plan. | 05/19/2026 | Standard alignment of director compensation with company performance. |
Stakeholder Impact
- Shareholders experience minor dilution from the issuance of new equity.
Next Steps
- Vesting of the granted RSUs and options on May 19, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/19/2026 | Date of grant for RSUs and stock options. |
| 05/21/2026 | Date of filing for the Form 4. |
| 05/19/2027 | Vesting date for the granted RSUs and stock options. |
Keywords
Corbus Pharmaceuticals, CRBP, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.